RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

RXST 01.02.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur RXST Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - J.P. Morgan Healthcare Conference
  • 01.12.2025 - RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
  • 01.02.2025 - RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
PDF Version

ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) --(NASDAQ: RXST) –RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

RxSight’s management is scheduled to present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at:https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight®Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens®(LALTM/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDDTM) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found atwww.rxsight.com.

Company Contact:Shelley B. ThunenChief Financial Officersthunen@rxsight.com

Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@rxsight.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com